

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2005

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2005						
<i>(Rs. in thousands)</i>						
Sr. No.	Particulars	Quarter ended 30.09.2005 (Audited)	Quarter ended 30.09.2004 (Audited)	Half-year ended 30.09.2005 (Audited)	Half-year ended 30.09.2004 (Audited)	Year ended 31.03.2005 (Audited)
1.	Net Sales	1,775,671	1,705,588	3,326,484	3,307,995	6,463,624
2.	Other Income	10,641	34,473	28,890	71,064	157,987
3.	Total Expenditure (a+b+c+d+e)	1,290,687	1,160,075	2,411,010	2,285,713	4,535,670
	a. (Increase)/decrease in stock in trade	(64,275)	72,480	(81,448)	100,556	(30,420)
	b. Consumption of Raw Materials and Traded goods	1,043,858	805,269	1,918,552	1,572,237	3,471,966
	c. Power cost	70,749	58,659	138,652	116,052	245,990
	d. Employee cost	168,401	117,855	211,411	229,581	420,435
	e. Other Expenses	131,954	105,772	223,843	267,287	427,699
4.	Profit before Interest, Depreciation & Taxes (1+2-3)	495,625	579,996	944,364	1,093,346	2,085,941
5.	Interest and finance charges	1,401	5,659	4,003	12,160	19,931
6.	Depreciation	57,296	39,976	113,305	78,800	180,915
7.	Profit Before Taxation (4-5-6)	436,928	534,411	827,056	1,002,386	1,885,095
8.	Provision for current tax	86,118	31,640	154,167	55,060	98,298
9.	Provision for deferred tax	(2,881)	5,052	(9,697)	13,062	42,917
10.	Net Profit (7-8-9)	359,691	497,719	682,586	934,264	1,743,880
11.	Paid-up equity share capital	500,000	500,000	500,000	500,000	500,000
12.	Reserves excluding revaluation reserves	7,143,528	5,852,685	7,143,528	5,852,685	6,445,082
13.	Earnings per share (Par value of Rs. 5/-)					
	- Basic - (in Rs.)	3.70	5.26	7.15	9.88	18.43
	- Diluted - (in Rs.)	3.65	5.14	7.05	9.64	18.00
14.	Aggregate of Non-Promoter Shareholding					
	- Number of Shares	35,452,439	35,452,439	35,452,439	35,452,439	35,452,439
	- Percentage of shareholding	35.45%	35.45%	35.45%	35.45%	35.45%

SEGMENT REPORTING FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2005						
<i>(Rs. in thousands)</i>						
Sr. No.	Particulars	Quarter ended 30.09.2005 (Audited)	Quarter ended 30.09.2004 (Audited)	Half-year ended 30.09.2005 (Audited)	Half-year ended 30.09.2004 (Audited)	Year ended 31.03.2005 (Audited)
1.	Segment revenue					
	a. Enzymes	239,679	252,463	461,768	477,692	980,942
	b. Pharma	1,558,319	1,472,059	2,910,999	2,868,866	5,566,810
	Total	1,797,998	1,724,522	3,372,767	3,346,558	6,547,752
	Less: Inter-segment revenue	22,327	18,924	46,283	38,563	84,128
	Net sales/Income from operations	1,775,671	1,705,598	3,326,484	3,307,995	6,463,624
2.	Segment results					
	Profit before interest, depreciation and tax from each segment					
	a. Enzymes	101,119	120,922	216,023	234,043	475,237
	b. Pharma	583,116	564,086	1,054,864	1,183,419	2,074,971
	c. Others	-	(22,338)	-	(33,107)	(36,354)
	Total	684,235	662,670	1,270,887	1,384,355	2,513,854
	Less: Interest	1,401	5,659	4,003	12,160	19,931
	Depreciation	57,296	39,976	113,305	78,800	180,915
	Unallocated corporate expenses net of unallocable income	188,610	82,674	326,523	291,009	427,913
	Profit before tax	436,928	534,411	827,056	1,002,386	1,885,095
3.	Capital employed					
	a. Enzymes	440,149	407,970	440,149	407,970	503,641
	b. Pharma	5,796,327	3,421,078	5,796,327	3,421,078	4,601,939
	c. Unallocable corporate assets	2,069,547	3,795,002	2,069,547	3,795,002	3,069,189
	Less: Corporate liabilities	648,998	1,256,263	648,998	1,256,263	1,215,385
	Total capital employed	7,657,025	6,367,787	7,657,025	6,367,787	6,959,384
	Less: Revaluation Reserve	13,497	15,102	13,497	15,102	14,302
	Capital employed net of revaluation reserves	7,643,528	6,352,685	7,643,528	6,352,685	6,945,082

Note: The primary reporting of the Company has been performed on the basis of business segment. The Company is organised into two business segments, enzymes and active pharmaceutical ingredients ('Pharma'). Segments have been identified and reported based on the nature of the products, the risks and returns, the organisation structure and the internal financial reporting systems.

CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2005						
<i>(Rs. in thousands)</i>						
Sr. No.	Particulars	Quarter ended 30.09.2005 (Audited)	Quarter ended 30.09.2004 (Audited)	Half-year ended 30.09.2005 (Audited)	Half-year ended 30.09.2004 (Audited)	Year ended 31.03.2005 (Audited)
1.	Net Sales	2,005,590	1,860,944	3,745,162	3,602,917	7,125,664
2.	Other Income	11,259	34,020	29,037	70,576	156,247
3.	Total Expenditure (a-b+c+d+e)	1,416,488	1,245,076	2,651,112	2,450,962	4,887,081
	a. (Increase)/decrease in stock in trade	(64,275)	72,480	(81,448)	100,556	(30,420)
	b. Consumption of Raw Materials & Traded goods	1,093,752	834,440	2,005,976	1,630,712	3,607,601
	c. Power cost	77,500	60,268	152,106	119,367	255,726
	d. Employee cost	157,969	158,442	307,899	308,629	568,893
	e. Other Expenses	151,542	119,446	266,579	291,688	485,281
4.	Profit before Interest, Depreciation & Taxes (1+2-3)	600,361	649,888	1,123,087	1,222,531	2,394,830
5.	Interest and finance charges	1,532	5,723	4,343	12,451	20,282
6.	Depreciation	73,815	47,285	144,944	93,235	223,445
7.	Profit Before Taxation (4-5-6)	525,014	596,879	973,800	1,116,845	2,151,103
8.	Provision for current tax	95,765	33,805	169,283	59,314	128,341
9.	Provision for deferred tax	(1,981)	5,052	(9,146)	13,062	57,726
10.	Net Profit before minority interest (7-8-9)	431,229	558,022	813,663	1,044,469	1,965,036
11.	Add/(Less): Minority interest	4,195	4,289	8,857	4,285	10,414
12.	Net Profit (10+11)	435,424	562,311	822,520	1,048,754	1,975,450
13.	Paid-up equity share capital	500,000	500,000	500,000	500,000	500,000
14.	Reserves excluding revaluation reserves	7,729,320	6,181,465	7,729,320	6,181,465	6,890,940
15.	Earnings per share (Par value of Rs 5/-)					
	- Basic - (in Rs.)	4.56	5.95	8.61	11.09	20.88
	- Diluted - (in Rs.)	4.50	5.80	8.49	10.82	20.39

Note: The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in India and comply with the Accounting Standard (AS 21) on Consolidated Financial Statements, issued by the Institute of Chartered Accountants of India to reflect the financial position and the results of operations of Biocon together with its subsidiary companies, Syngene, Clinigene and JV company, Biocon Biopharmaceuticals.

Notes:

- The earnings considered in ascertaining the Company's earnings per share comprise of the net profit after tax. The number of shares used in computing the basic earnings per share is the weighted average number of shares outstanding during the period/year. The number of shares used in computing diluted earnings per share comprises the weighted average share considered for deriving basic earnings per share, and also the weighted average number of shares, if any which would have been issued on the conversion of all dilutive potential equity shares. In accordance with the revised SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 (Revised), accounts of the ESOP Trust has been consolidated with the Company.
- Total number of shareholder complaints pending at the beginning of the quarter was 1. Complaints received during the quarter were 144. The complaints resolved during the quarter were 144. Complaints pending for redressal as at the end of the quarter was 1, which has now been resolved.
- The above results were reviewed by the Audit committee on October 18, 2005 and then approved by the Board of Directors at their meeting held on October 19, 2005.
- The figures have been reclassified wherever required, to conform with the classification in the financial statements for the quarter and half year ended September 30, 2005.

For and on behalf of the Board

Sd/-
Kiran Mazumdar Shaw
 Managing Director

Place: Bangalore Date: Oct. 19, 2005